Does Trimetazidine Improve Outcomes After Successful PCI?

Even with successful revascularization, persistent or recurrent angina is a common limitation of percutaneous coronary intervention (PCI), often leading to repeat hospitalizations and invasive cardiac procedures. These anginal episodes can have various causes, including incomplete revascularization, microvascular disease, and acute coronary syndromes. The non–FDA-approved medication trimetazidine is a second-line antianginal agent approved in many countries for patients with stable angina. Unlike most antianginal medications, trimetazidine has no hemodynamic effects and is thought to relieve angina predominantly by modifying myocardial fatty-acid metabolism and improving myocardial energetics. Hypothesizing that trimetazidine might improve …